The SELECT trial, which included patients with CV disease and overweight or obesity (many also had increased risk for diabetes), showed a reduction in major adverse CV events (defined as CV death, nonfatal heart attack, and nonfatal stroke) of 20% with weekly subcutaneous semaglutide 2.4 mg
PubMed ID: 17018654 Raun K et al
How much is Zepbound on Ro
Glutathione helps your liver and detox pathways to handle it efficiently
Indias drug regulator, the CDSCO, has stated that GLP-1 obesity drugs are approved with the condition that they be prescribed only by qualified specialists after proper evaluation, per PIB, Government of India, 2025-26
Tirzepatide combines the effect of two incretins - GLP-1 and the glucose-dependent insulinotropic polypeptide (GIP) - and is therefore also known as Twincretin [20]